PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease
Our data indicate that endothelial function improved with evolocumab treatment in high-risk patients on statin therapy with preexisting cardiovascular disease. Our results contribute to the mechanistic explanation why lower incidence of the cardiovascular composite endpoint has been demonstrated in the FOURIER study.
Authors
- Robert Pietschner (ORCID: https://orcid.org/0000-0002-8867-2156)
- Laura A. Berner (ORCID: https://orcid.org/0000-0002-1430-8028)
- Kristina Striepe
- Roland Erich Schmieder (ORCID: https://orcid.org/0000-0003-2356-5883)
- Dennis Kannenkeril (ORCID: https://orcid.org/0000-0002-2345-238X)
- Mario Schiffer (ORCID: https://orcid.org/0000-0002-8414-1470)
- Julie Kolwelter
- Agnes Bosch (ORCID: https://orcid.org/0000-0001-6952-4660)
- Christian Ott
- Stephan Achenbach
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Comprehensive Cancer Center Erlangen (DE)
Publication Details
- Journal
- Clinical Research in Cardiology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1007/s00392-024-02556-6
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- Amgen
- Universitätsklinikum Erlangen